Given that DPP-4 inhibitors are therapeutic drugs for diabetes that target a part of the CD26 molecule, which is a costimulatory molecule involved in T cell activation, there is concern over their effect on immune mechanisms. The gene discussed is DPP4; the disease is diabetes mellitus.